Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/belzutifan-combo-could-be-second-line-option-advanced-rcc-2026a10006hc?src=rss
Author :
Publish date : 2026-03-02 21:33:00
Copyright for syndicated content belongs to the linked Source.
